Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
In the last few years great progress has been made in the search for the cellular and molecular mechanisms of chronic kidney disease and its progression to end-stage renal failure. The possibility of remission/regression of chronic nephropathy has become a reality for some patients on therapy based on renin-angiotensin system blockade - an example of how a public health concern can be successfully addressed by translational medicine. This review describes experimental and clinical investigations documenting the advances achieved in the management of chronic kidney diseases by targeting angiotensin II.
Department of Biomedical Engineering, Mario Negri Institute for Pharmacological Research, Bergamo, Italy. daniela.macconi@marionegri.it
Daniela
D
Macconi
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy / Q000503:physiopathology; D008954:Models, Biological; D011507:Proteinuria / Q000188:drug therapy / Q000503:physiopathology; D012074:Remission Induction; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II